Citations

Clear

3942 citation(s) found for "To, Van".

ACR Appropriateness Criteria ® Spinal Bone Metastases
Lo, Simon Shek-Man, Lutz, Stephen, Chang, Eric L. , Galanopoulos, Nicholas, Howell, David D., Kim, Edward Y. , Konski, André , Pandit-Taskar, Neeta D., Rose, Peter S. , Ryu, Samuel , Silverman, Larry N., Sloan, Andrew E. , Poznak, Catherine Van

Mayo Clinic

Journal of Palliative Medicine | November 20, 2012 | Volume: 16 | Issue: 1 | Pages: 9-19

10.1089/jpm.2012.0376 | PMID 23167547 Get It

Psychosocial Outcomes for Children With Nonalcoholic Fatty Liver Disease Over Time and Compared With Obese Controls
Kerkar, Nanda , D’Urso, Christine, Nostrand, Kelsey Van, Kochin, Israel, Gault, Allison, Suchy, Frederick J., Miloh, Tamir , Arnon, Ronen , Chu, Jaime , Annunziato, Rachel A.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | November 17, 2012 | Volume: 56 | Issue: 1 | Pages: 77-82

10.1097/mpg.0b013e31826f2b8c | PMID 22925921 Get It

ABSTRACTObjectives:Children with nonalcoholic fatty liver disease (NAFLD) experience compromised quality of life (QOL) akin to those with other chronic disease. Our objectives were to examine the association between NAFLD and QOL as well as other psychosocial outcomes, to compare psychosocial outcomes to obese children without known NAFLD, and to determine whether present standard care for NAFLD results in weight loss and improvement in psychosocial outcomes longitudinally.Methods:Children with NAFLD between 8 and 18 years and obese control children without known NAFLD were consented to complete a brief psychosocial battery examining depression (Children's Depression Inventory), QOL (Pediatric Quality of Life Inventory; PedsQL), and effect of weight on self‐esteem (Body‐Esteem Scale for Adolescents and Adults) at baseline; and additionally for the NAFLD group after at least 6 months.Results:A total of 48 children with NAFLD and 40 obese control children were enrolled. The PedsQL scores were not significantly different but the CDI total score and subscales of negative mood, ineffectiveness, and negative self‐esteem as well as all of the 3 subscales of BESAA, appearance, attribution, and weight were worse in the NAFLD group compared with obese controls. The PedsQL scores also did not change after standard care in the 33 patients with NAFLD who completed the follow‐up evaluations, but the CDI score differed between those whose body mass index improved or not.Conclusions:Children with NAFLD have higher levels of depression than obese controls. Outcomes did not improve with standard care. Larger longitudinal studies and appropriate interventions are required in this area.
Correlates of Moderate-to-Vigorous Physical Activity Participation in Adults With Intellectual Disabilities
Bodde, Amy E. , Seo, Dong‐Chul , Frey, Georgia C. , Puymbroeck, Marieke Van , Lohrmann, David K.

Mayo Clinic

Health Promotion Practice | November 10, 2012 | Volume: 14 | Issue: 5 | Pages: 663-670

10.1177/1524839912462395 | PMID 23142762 Get It

Adults with intellectual disabilities (ID) have low levels of physical activity and higher than average rates of related chronic health conditions. Understanding correlates of their physical activity participation may improve health promoting interventions. Forty-two adults with ID participated in a physical activity study. Physical activity knowledge and skills, awareness of recommendations and demographic characteristics were analyzed for their association with moderate-to-vigorous physical activity (MVPA) participation measured by accelerometers. Five variables were significantly correlated with MVPA. Body mass index was inversely correlated with MVPA, and gender, job location, job tasks, and place of residence were all significantly associated with MVPA. Understanding correlates of physical activity in this population will help inform disability service and health promotion professionals in future research and health intervention design.
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Bozi, Maria , Barcikowska, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Jamrozik, Zygmunt , Krygowska‐Wajs, Anna, Lesage, Suzanne , Lill, Christina M. , Lin, Juei‐Jueng , Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Libioulle, Cécile , Murata, Miho, Mok, Vincent , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Meitnger, Thomas, Zimprich, Alexander , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Strom, Tim M., Theuns, Jessie , Tan, Eng King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Broeckhoven, Christine Van , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yomono, Harumi, Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , Lang, Anthony E , Ross, Owen A , Zimprich, Alexander , Brice, Alexis

Mayo Clinic

Journal of Medical Genetics | November 2, 2012 | Volume: 49 | Issue: 11 | Pages: 721-726

10.1136/jmedgenet-2012-101155 | PMID 23125461 Get It

Background Two recent studies identified a mutation (p.Asp620Asn) in the vacuolar protein sorting 35 gene as a cause for an autosomal dominant form of Parkinson disease . Although additional missense variants were described, their pathogenic role yet remains inconclusive. Methods and results We performed the largest multi-center study to ascertain the frequency and pathogenicity of the reported vacuolar protein sorting 35 gene variants in more than 15,000 individuals worldwide. p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases and not in healthy controls, p.Leu774Met in 6 cases and 1 control, p.Gly51Ser in 3 cases and 2 controls. Overall analyses did not reveal any significant increased risk for p.Leu774Met and p.Gly51Ser in our cohort. Conclusions Our study apart from identifying the p.Asp620Asn variant in familial cases also identified it in idiopathic Parkinson disease cases, and thus provides genetic evidence for a role of p.Asp620Asn in Parkinson disease in different populations worldwide.
Cobalt and Chromium Measurement in Patients with Metal Hip Prostheses
Estey, Mathew P., Straeten, Catherine Van Der , Tower, Stephen S. , Hart, Alister , Moyer, Thomas P. , Diamandis, Eleftherios P.

Mayo Clinic

Clinical Chemistry | November 1, 2012 | Volume: 59 | Issue: 6 | Pages: 880-886

10.1373/clinchem.2012.193037 | PMID 23115056 Get It

Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1
Hilbers, Florentine , Hoogerbrugge, Nicoline, Oosterwijk, Jan C., Collée, Margriet J., Peterlongo, Paolo , Radice, Paolo , Manoukian, Siranoush , Feroce, Irène , Capra, F, Guidugli, Lucia, Offit, Kenneth, Shah, Sohela, Campbell, Ian , Thompson, Ella R. , James, Paul A. , Trainer, Alison H., Gracia, Javier, Devilee, Peter , Hoogerbrugge, Nicoline , Wijnen, Juul , Hoogerbrugge, Nicoline, Collée, Margriet , Couch, Fergus J. , Wang, Xianshu , Benı́tez, Javier , Asperen, Christi J. van , James, Paul , Peterlongo, Paolo , Radice, Paolo , Campbell, Ian G , Devilee, Peter , Manoukian, Siranoush

Mayo Clinic

Journal of Medical Genetics | October 10, 2012 | Volume: 49 | Issue: 10 | Pages: 618-620

10.1136/jmedgenet-2012-101191 | PMID 23054243 Get It

Background Recently, rare germline variants in XRCC2 were detected in non-BRCA1/2 familial breast cancer cases, and a significant association with breast cancer was reported. However, the breast cancer risk associated with these variants needs further evaluation. Methods The coding regions and exon–intron boundaries of XRCC2 were scanned for mutations in an international cohort of 3548 non-BRCA1/2 familial breast cancer cases and 1435 healthy controls using various mutation scanning methods. Predictions on functional relevance of detected missense variants were obtained from three different prediction algorithms. Results The only protein-truncating variant detected was found in a control. Rare non-protein-truncating variants were detected in 20 familial cases (0.6%) and nine healthy controls (0.6%). Although the number of variants predicted to be damaging or neutral differed between prediction algorithms, in all instances these categories were evenly represented among cases and controls. Conclusions Our data do not confirm an association between XRCC2 variants and breast cancer risk, although a relative risk smaller than two could not be excluded. Variants in XRCC2 are unlikely to explain a substantial proportion of familial breast cancer.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Boxer, Adam L. , Huey, Edward D. , Hu, William T. , Rosen, Howard J. , Kramer, Joel H. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J., Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Jackson, George R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Abushakra, Susan, Lewcock, Joseph W. , Farese, Robert V. , Kenet, Robert O. , LaFerla, Frank M. , Perrin, Steve, Whitaker, Steve, Grossman, Murray, Gold, Michael , Kao, Aimee W. , Knopman, David S. , Honig, Lawrence S. , Mesulam, Marsel M. , Boeve, Bradley F. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H , Hu, William T.

Mayo Clinic

Alzheimer's & Dementia | October 10, 2012 | Volume: 9 | Issue: 2 | Pages: 189-198

10.1016/j.jalz.2012.03.003 | PMID 23062850 Get It

Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Boxer, Adam L. , Huey, Edward D. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J. , Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Farese, Robert V. , Gold, Michael , Kao, Aimee W. , Knopman, David S. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | October 5, 2012 | Volume: 9 | Issue: 2 | Pages: 176-188

10.1016/j.jalz.2012.03.002 | PMID 23043900 Get It

Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled “FTD, the Next Therapeutic Frontier,” which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11
Siddiq, Afshan , Chen, Gary K., Lindström, Sara, Eccles, Diana , Millikan, Robert C., Michailidou, Kyriaki , Beckmann, Lars , Aittomäki, Kristiina , Apicella, Carmel, Investigators, Australian Breast Cancer Tissue Bank, Baglietto, Laura , Bandera, Elisa V. , Beckmann, Matthias W. , Berg, Christine D. , Blomqvist, Carl , Brauch, Hiltrud , Brinton, Louise A. , Bui, Minh , Buring, Julie E. , Campa, Daniele , Carpenter, Jane, Chang‐Claude, Jenny, Chen, Constance, Clavel-Chapelon, Françoise, Cox, Angela , Cross, Simon S. , Czene, Kamila , Deming, Sandra L., Diasio, Robert B. , Diver, W. Ryan , Dunning, Alison M. , Durcan, Lorraine , Ekici, Arif B. , Fasching, Peter A. , Study, Familial Breast Cancer, Fejerman, Laura , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Gaudet, Mia M., Gerty, Susan M. , Rodriguez‐Gil, Jorge L. , Giles, Graham G. , Gils, Carla H. van , Graham, Nikki , Greco, Dario , Hankinson, Susan E. , Hartmann, Arndt, Hein, Rebecca, Heinz, Judith , Hoover, Robert N. , Hu, Jennifer J. , Huntsman, Scott , Irwanto, Astrid , Jacobs, Kevin B. , John, Esther M. , Justenhoven, Christina , Kolonel, Laurence N. , Coetzee, Gerhard A. , Lathrop, Mark, Lee, I‐Min , Lesnick, Timothy G. , Lichtner, Peter , Liu, Jianjun , Lund, Eiliv , Makalic, Enes , Martin, Nicholas G. , McLean, Catriona , Meijers‐Heijboer, Hanne , Meindl, Alfons , Miron, Penelope , Montgomery, Grant W. , Müller‐Myhsok, Bertram , Nickels, Stefan , Nyante, Sarah J. , Olswold, Curtis, Overvad, Kim , Palli, Domenico , Park, Daniel J. , Palmer, Julie R. , Peto, Julian , Rahman, Nazneen , Rivadeneira, Fernando , Schmutzler, Rita K. , Slager, Susan, Southey, Melissa C. , Stevens, Kristen N., Sinn, Hans‐Peter , Ross, Eric A. , Ríboli, Elio , Schumacher, Fredrick R. , Severi, Gianluca , Stone, Jennifer , Sund, Malin , Tapper, William , Thun, Michael J., Travis, Ruth C. , Turnbull, Clare , Uitterlinden, André G. , Waisfisz, Quinten , Wang, Zhaoming , Weaver, JoEllen , Schulz-Wendtland, Rüdiger, Nevanlinna, Heli , Easton, Douglas F., Hunter, David J. , Henderson, Brian E., García‐Closas, Montserrat , Kraft, Peter , Haiman, Christopher A. , Vachon, Celine M. , Zheng, Wei , Purrington, Kristen S. , Couch, Fergus J. , Stram, Daniel O. , Rhie, Suhn K. , Ambrosone, Christine B. , Amiano, Pilar , Investigators, Australian Breast Cancer Tissue Bank, Bernstein, Leslie , Bui, Minh , Buys, Saundra S. , Chasman, Daniel I. , Study, Familial Breast Cancer, Feigelson, Heather Spencer , Fletcher, Olivia , Godwin, Andrew K. , Hall, Per N , Hankinson, Susan E. , Hopper, John L. , Ingles, Sue A. , Isaacs, Claudine , Kaaks, Rudolf , Marchand, Loı̈c Le , Lee, Adam M. , Meindl, Alfons , Monroe, Kristine R. , Pathak, Harsh B. , Pharoah, Paul D.P. , Schmidt, Daniel F. , Press, Michael F. , Ridker, Paul M. , dos‐Santos‐Silva, Isabel , Wang, Xianshu , Wilkens, Lynne R. , Berg, David Van Den , Zheng, Wei , Ziegler, Regina G. , Ziv, Elad , Chanock, Stephen Jacob , Vachon, Celine M. , Nevanlinna, H , Giles, Graham G , Eccles, Diana , John, Esther M , Palli, Domenico , Southey, Melissa C , Martin, Nicholas G , Sinn, Peter , Travis, Ruth C , Wang, Zhaoming , Dunning, Alison M , Cox, Angela , García-Closas, Montserrat , Severi, Gianluca , Makalic, Enes , Ekici, Arif B , Michailidou, Kyriaki , Palmer, Julie R , Kraft, Peter , Zheng, Wei , Figueroa, Jonine D , Nyante, Sarah , Czene, Kamila , Stone, Jennifer , Riboli, Elio , Sund, Malin , Baglietto, Laura , Purrington, Kristen S , Mclean, Catriona , Brauch, Hiltrud , Liu, Jing , Bandera, Elisa V.

Mayo Clinic

Human Molecular Genetics | September 14, 2012 | Volume: 21 | Issue: 24 | Pages: 5373-5384

10.1093/hmg/dds381 | PMID 22976474 Get It